MULTIPARTICULATE SYSTEMS FOR TREATMENT OF COLON CANCER: CURRENT OUTLOOK AND FUTURE PERSPECTIVES

Tilashmi Baghel [1], Sandeep Kumar Sonkar [2*]

[1]Department of Pharmaceutics, Shri Rawatpura Sarkar Institute of Pharmacy, Kumhari, Dist. Durg, Chhattisgarh

[2]Department of Pharmaceutics, Rungta College of Pharmaceutical Sciences and Research, Raipur, Chhattisgarh

***Corresponding Author:**
Dr. Sandeep Kumar Sonkar
Associate Professor,
Krishna's Vikash Institute of pharmaceutical sciences and research (KVIPSR)
Raipur, Chhattisgarh

Abstract

Colon cancer remains a leading cause of cancer-related mortality globally, necessitating advanced drug delivery systems to enhance treatment efficacy while minimizing systemic toxicity. Multiparticulate systems (MPS)—including microspheres, nanoparticles, pellets, and hydrogels—have emerged as a revolutionary platform for colon-targeted therapy. These systems leverage pH sensitivity, enzymatic triggers, and microbial interactions to achieve site-specific drug release, significantly improving bioavailability and reducing off-target effects. Recent innovations in biomaterials, such as stimuli-responsive polymers and bioengineered coatings, have further refined their precision, enabling controlled, sustained, and programmable drug delivery. MPS also facilitate combination therapy by co-encapsulating chemotherapeutics, biologics, and immunomodulators with tailored release kinetics. Despite their promise, challenges in scalable manufacturing, regulatory compliance, and clinical translation persist.

Advances in nanotechnology, 3D printing, and artificial intelligence are addressing these limitations, paving the way for next-generation MPS with applications in personalized oncology. This review comprehensively examines the current state of MPS for colon cancer, highlighting their mechanisms, preclinical and clinical progress, and future directions, including integration with CRISPR-based therapies and microbiome modulation.

Keywords: Multiparticulate systems, Colon cancer, Targeted drug delivery, pH-sensitive polymers, Controlled release, Combination therapy

1. Introduction

Colon cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related deaths globally. Conventional chemotherapy, while effective, is often associated with severe systemic side effects due to non-specific drug distribution. Targeted drug delivery systems, particularly multiparticulate systems, have gained significant attention for their ability to localize drug release in the colonic region, thereby minimizing off-target effects and improving therapeutic efficacy.

Multiparticulate systems consist of small, discrete units such as pellets, beads, microparticles, or nanoparticles that can be engineered for controlled or site-specific drug release. These systems offer several advantages over single-unit dosage forms, including uniform drug distribution in the gastrointestinal tract (GIT), reduced risk of dose dumping, and flexibility in combining multiple drugs or release profiles. This review explores the various types of multiparticulate systems used in colon cancer therapy, their formulation approaches, and the latest advancements in the field.

2. Rationale for Multiparticulate Systems in Colon Cancer Therapy

The colon presents a unique environment for drug delivery due to its relatively neutral pH, prolonged transit time, and presence of microbial enzymes. These characteristics

can be exploited to design multiparticulate systems that release drugs specifically in the colon. The key advantages of MPS for colon cancer treatment include:

- **Enhanced Targeting:** Multiparticulate systems can be designed to respond to colonic pH, enzymatic activity, or transit time, ensuring localized drug release.
- **Reduced Systemic Toxicity:** By minimizing drug exposure to the upper GIT, MPS decrease adverse effects such as nausea, vomiting, and mucosal damage.
- **Improved Drug Stability:** Encapsulation protects sensitive drugs from degradation in the stomach's acidic environment.
- **Controlled and Sustained Release:** MPS can provide prolonged drug release, maintaining therapeutic concentrations over an extended period.
- **Combination Therapy Potential:** Different particles can be loaded with multiple drugs or agents (e.g., chemotherapeutics and immunomodulators) for synergistic effects.

3. Types of Multiparticulate Systems for Colon Cancer Treatment

Multiparticulate systems can be broadly classified based on their size, composition, and drug release mechanisms. The most commonly explored systems include:

3.1. Microspheres and Microparticles

3.1.1. Structural Characteristics

Microspheres are spherical, monolithic, or reservoir-type particulate systems with diameters typically ranging from 1 to 1000 micrometers (μm). Their spherical geometry ensures uniform drug distribution, high surface-area-to-volume ratio, and excellent flow properties, making them ideal for oral drug delivery. These particles can be engineered as:

- **Matrix systems** (drug dispersed uniformly within the polymer)
- **Reservoir systems** (drug core surrounded by a polymeric membrane)

The structural integrity and release kinetics of microspheres depend on the polymer composition, cross-linking density, and fabrication technique.

3.1.2. Biodegradable Polymers in Microsphere Formulation

The choice of polymer critically influences drug loading, release profile, and biodegradability. Commonly used polymers include:

3.1.2.1. Natural Polymers

- **Chitosan**: A cationic polysaccharide derived from chitin, known for its mucoadhesive properties, biocompatibility, and ability to enhance paracellular drug absorption. It is enzymatically degraded by colonic microbiota.
- **Alginate**: An anionic polysaccharide that forms hydrogels in the presence of divalent cations (e.g., Ca^{2+}). Its porosity can be modulated for controlled drug release.
- **Pectin**: A galacturonic acid-rich polysaccharide degraded specifically by colonic pectinases, making it ideal for colon-targeted delivery.

3.1.2.2. Synthetic Polymers

- **Poly(lactic-co-glycolic acid) (PLGA)**: A FDA-approved copolymer that undergoes hydrolysis into lactic and glycolic acid, ensuring controlled degradation. PLGA microspheres provide sustained release from days to months, depending on the lactide:glycolide ratio.
- **Eudragit® (pH-sensitive polymers)**:
    - **Eudragit® S100/SL100**: Dissolves at pH >7 (colon-specific release).
    - **Eudragit® L100/L30D-55**: Dissolves at pH >6 (ileo-colonic release).
- **Poly(ε-caprolactone) (PCL)**: Slower degradation than PLGA, suitable for long-term drug release.

3.1.3. Drug Loading and Encapsulation Techniques

Microspheres can encapsulate a wide range of chemotherapeutic agents, including:

- **5-Fluorouracil (5-FU)** – A pyrimidine analog inhibiting thymidylate synthase.
- **Oxaliplatin** – A platinum-based DNA cross-linking agent.
- **Irinotecan** – A topoisomerase I inhibitor.
- **Curcumin & Natural Compounds** – For adjuvant therapy.

Encapsulation Methods:

1. **Emulsion Solvent Evaporation (O/W, W/O/W)** – Suitable for hydrophobic drugs in PLGA.
2. **Ionotropic Gelation** – Used for chitosan/alginate microspheres (e.g., Ca^{2+} cross-linking).
3. **Spray Drying** – Rapid production of dry powder microspheres.
4. **Coacervation/Phase Separation** – For reservoir-type microspheres.

3.1.4. Colon-Targeted Release Mechanisms

To ensure site-specific drug delivery, microspheres are designed with:

a) pH-Sensitive Release

- **Eudragit®-coated microspheres** remain intact in the stomach (pH 1–3) and small intestine (pH 6–6.5) but dissolve in the colon (pH ≥7).
- **Limitation**: Inter-patient variability in gut pH may affect release consistency.

b) Enzyme-Triggered Degradation

- **Azo polymers** (e.g., poly(vinyl azo)) are cleaved by **azoreductase** from colonic bacteria.
- **Polysaccharides** (e.g., chitosan, pectin, dextran) are degraded by microbial enzymes (e.g., pectinase, dextranase).

c) Redox-Responsive Systems

- Disulfide bond-containing polymers degrade in the **hypoxic, reducing environment** of colon tumors.

3.1.5. Advantages over Conventional Dosage Forms

- **Reduced Gastric Irritation**: Avoids premature release of cytotoxic drugs in the stomach.
- **Enhanced Bioavailability**: Protects drugs from acidic/enzymatic degradation.
- **Dose Sparing**: Localized delivery reduces systemic toxicity (e.g., neurotoxicity of oxaliplatin).
- **Combination Therapy**: Different microspheres can co-deliver chemo/immunotherapy agents.

3.1.6. Challenges and Optimization Strategies

Challenge	Potential Solution
Burst Release	Use of cross-linked polymers or double-layered microspheres.
Poor Drug Loading	Hydrophilic drug-polymer conjugates or nanoemulsion-based loading.
Variable Gut Transit	Combination of pH-dependent and time-release coatings.
Scalability Issues	Advanced techniques like microfluidics or supercritical fluid extraction.

3.1.7. Future Directions

- **Stimuli-Responsive Smart Microspheres**: Incorporating magnetic, ultrasound, or enzyme-triggered release.
- **3D-Printed Microsphere Arrays**: For personalized colon cancer therapy.
- **Microsphere-Hydrogel Hybrids**: For localized depot therapy post-surgical resection.
- **Theragnostic Microspheres**: Combining drug delivery with imaging (e.g., MRI/fluorescence).

3.2. Nanoparticles

3.2.1. Nanoscale Advantages in Colon Cancer Therapeutics

Nanoparticles (NPs), with their 1–1000 nm size range, exploit unique biophysical interactions at the cellular and subcellular level to overcome limitations of conventional chemotherapy. Their enhanced permeability and retention (EPR) effect facilitates passive accumulation in tumor tissues, while their high surface-area-to-volume ratio enables:

- Superior cellular uptake via endocytosis (clathrin-mediated, caveolae-dependent, or macropinocytosis).
- Deep tumor penetration through leaky vasculature (pore size: 200–2000 nm in tumors vs. <10 nm in normal tissues).
- Lymphatic system evasion due to optimal size (>10 nm avoids renal clearance, <150 nm avoids Kupffer cell uptake).

3.2.2. Classification and Engineering of Colon-Targeted Nanoparticles

3.2.2.1. Polymeric Nanoparticles

Composition:

- **Natural polymers**: Chitosan (cationic, mucoadhesive), alginate (anionic, Ca^{2+}-crosslinkable), hyaluronic acid (CD44-targeting).

- **Synthetic polymers**: PLGA (hydrolytically degradable), PCL (slow degradation), dendrimers (hyperbranched, high drug-loading).

Drug Loading Strategies:

- **Encapsulation efficiency optimization**: Double-emulsion (W/O/W) for hydrophilic drugs (e.g., 5-FU), nanoprecipitation for hydrophobic drugs (e.g., paclitaxel).
- **Surface functionalization**: PEGylation ("stealth effect"), cell-penetrating peptides (e.g., TAT, RGD).

3.2.2.2. Lipid-Based Nanoparticles

Types:

- **Solid lipid nanoparticles (SLNs)**: Triglyceride cores (e.g., Compritol® 888 ATO) for sustained release.
- **Nanostructured lipid carriers (NLCs)**: Blend of solid and liquid lipids (e.g., glyceryl monostearate + oleic acid) for higher payloads.
- **Liposomes**: Phosphatidylcholine bilayers encapsulating hydrophilic (core) and hydrophobic (membrane) drugs.

Colon-Specific Modifications:

- **pH-sensitive lipids**: DOPE/CHEMS (fusogenic at pH >6.5).
- **Enzyme-responsive lipids**: Azo-conjugated lipids cleaved by azoreductase.

3.2.2.3. Inorganic Nanoparticles

Type	Material	Unique Properties	Colon Cancer Application
Gold NPs	Au (5–100 nm)	Surface plasmon resonance (photothermal therapy), facile thiol conjugation	CT imaging, radiosensitization

Type	Material	Unique Properties	Colon Cancer Application
Silica NPs	Mesoporous SiO_2	High pore volume (>1 cm^3/g) for drug loading	Controlled release of oxaliplatin
Iron Oxide	Fe_3O_4 (SPIONs)	Superparamagnetic (MRI contrast)	Magnetic hyperthermia + drug delivery

3.2.3. Active Targeting Strategies for Tumor Specificity

3.2.3.1. Ligand-Receptor Systems Exploited in Colon Cancer:

- **Folate receptors** (overexpressed in 80% of colon cancers): Folic acid-conjugated NPs (KD ≈ 10^{-9} M).
- **CD44 receptors**: Hyaluronic acid-coated NPs (internalization via receptor-mediated endocytosis).
- **EGFR-targeting**: Cetuximab-functionalized NPs for KRAS-mutant tumors.
- **Lectins**: Wheat germ agglutinin (WGA) for mucoadhesion to colonic glycocalyx.

3.2.3.2. Dual-Targeting Approaches:

- **pH/enzyme-responsive NPs**: E.g., PLGA-PEG-folate NPs with matrix metalloproteinase (MMP-2)-cleavable linkers.

3.2.4. Therapeutic Cargos Beyond Small Molecules

- **siRNA/miRNA Delivery**: Chitosan NPs for silencing oncogenes (e.g., survivin, KRAS).
- **CRISPR-Cas9**: Gold NP polyplexes for gene editing (e.g., APC tumor suppressor restoration).
- **Immunomodulators**: PD-L1 siRNA + oxaliplatin co-delivery in lipid-polymer hybrid NPs.

3.2.5. In Vivo Performance and Barriers

Pharmacokinetic Challenges:

- **Mucus penetration**: PEGylation or mucolytic agents (e.g., N-acetylcysteine) to overcome mucin mesh (pore size: 50–1800 nm).
- **Tumor heterogeneity**: Hypoxia-responsive NPs (e.g., nitroimidazole derivatives) for deep penetration.

Biological Fate Studies:

- **Murine models**: Orthotopic CT26 tumors show 3–5× higher NP accumulation vs. free drug.
- **Human translational data**: Phase I trials of folate-targeted NPs (NCT00303836) demonstrate safety up to 150 mg/m².

3.2.6. Cutting-Edge Innovations

- **Exosome-Mimetic NPs**: Bioengineered vesicles with tumor-homing properties.
- **Digital Light Processing (DLP) 3D-printed NPs**: Microarchitected geometries for controlled shear-thinning release.
- **Quantum Dot Hybrids**: CdSe/ZnS NPs for real-time tracking + therapy ("theranostics").

7. Toxicity and Regulatory Landscape

Key Considerations:

- **Polymer degradation products**: PLGA → lactic/glycolic acid (generally recognized as safe, GRAS).
- **Inorganic NP clearance**: Gold/SiO_2 NPs >50 nm accumulate in liver/spleen (need renal-clearable variants <10 nm).

Clinical Pipeline:

- **Phase III**: Liposomal irinotecan (NCT04004463) for metastatic CRC.

- **Preclinical**: MnO_2 NPs to alleviate tumor hypoxia + potentiate immunotherapy.

8. Future Perspectives

- **Machine learning-optimized NP design**: Predicting in vivo performance via neural networks trained on NP libraries.
- **Synthetic biology**: Engineered bacterial NPs (e.g., E. coli Nissle 1917-derived) for microbiome-activated delivery.
- **Nanoparticle-hydrogel composites**: Injectable depot systems for post-surgical adjuvant therapy.

3.3. Pellets and Beads

3.3.1. Structural and Biopharmaceutical Fundamentals of Pellets

Pellets are spherical or near-spherical granules typically ranging from 100–2000 μm in diameter, engineered to meet stringent pharmacopeial standards (e.g., USP <705>). Their **multi-unit particulate system (MUPS)** architecture provides critical advantages over single-unit dosage forms:

- **Gastrointestinal Transit Properties**:
    - Even distribution across GI tract segments reduces "all-or-nothing" release risks
    - Sphincter-independent transit (vs. monolithic tablets) prevents pyloric retention
    - Size-optimized (500–1500 μm) to balance flowability and avoidance of M-cell uptake
- **Drug Release Kinetics**:
    - First-order release from individual pellets creates pseudo-zero-order kinetics at system level

- Independent pellet coatings allow **modular drug combinations** (e.g., 5-FU + leucovorin pellets in same capsule)

3.3.2. Core Formulation Technologies

3.3.2.1. Pelletization Techniques

Method	Mechanism	Colon Cancer Application
Extrusion-Spheronization	Wet mass extrusion through die (0.5–2 mm) followed by spheronizer polishing	High-dose cytotoxic agents (capecitabine)
Layering	Drug layered onto inert cores (sugar spheres, microcrystalline cellulose) in fluidized bed	Targeted biologics (bevacizumab conjugates)
Melt Congealing	Low-melt lipids (e.g., Gelucire®) containing drug cooled into spheres	Thermally sensitive drugs (irinotecan)
Spray Congealing	Atomized drug-polymer melts solidify in air	High-throughput production of NSAID pellets for CRC prevention

3.3.2.2. Core Matrix Engineering

- **Microenvironment-Responsive Matrices**:
  - **Pectin-chitosan cores**: Swell at colonic pH then degrade via pectinase
  - **Amylose-ethylcellulose**: Resistant to α-amylase until colonic bacterial degradation
- **Dual-Drug Loading Strategies**:
  - **Sandwich pellets**: Cytotoxic core (oxaliplatin) + outer anti-angiogenic layer (regorafenib)
  - **Gradient-release pellets**: Immediate-release 5-FU coating over sustained-release SN-38 core

3.3.3. Precision Coating Systems for Colon Targeting

3.3.3.1. pH-Dependent Coatings

- **Eudragit® FS 30D**:
    - Dissolution threshold: pH ≥7.0 (distal ileum/colon)
    - **Triple-layer coating**: Inner seal coat (HPMC), pH-sensitive layer (Eudragit), outer anti-tack coat (talc)
    - **In vivo performance**: Human gamma-scintigraphy shows <5% release before ascending colon

3.3.3.2. Time-Controlled Systems

- **Compressed Time-Delay Pellets**:
    - Inner drug core → erosion layer (HPMC K100M) → enteric coat (Eudragit L100)
    - **Pulsatile CRC regimens**: Dawn dosing (4am release) synchronized with circadian chemosensitivity

3.3.3.3. Microbiota-Activated Coatings

- **Azo Polymer Networks**:
    - Poly(2-hydroxyethyl methacrylate-co-styrene) crosslinked with azo bonds
    - Degradation kinetics: 12–18 hrs in human colon simulator models
- **Resistant Starch Coatings**:
    - High-amylose maize starch (Hylon® VII) requires bacterial α-glucosidase for dissolution

3.3.4. Advanced Functionalization Strategies

3.3.4.1. Mucoadhesive Modifications

- **Thiolated Polymers**:

- Chitosan-TGA (thioglycolic acid conjugate) forms disulfide bonds with colonic mucin
- Increases residence time from 8±2 hrs to 22±4 hrs in porcine models

3.3.4.2. Tumor-Penetrating Architectures

- **Hierarchical Pellets**:
  - Macropellet (1000 μm) containing hundreds of nanoparticles (150 nm)
  - "Nest-in-pellet" system enables sequential release: pellet → nanoparticles → tumor penetration

3.3.5. Manufacturing and Scale-Up Considerations

3.3.5.1. Process Analytical Technology (PAT)

- **In-line NIR spectroscopy**: Real-time monitoring of coating thickness (RSD <3%)
- **Micro-CT Quality Control**: 3D structural analysis of coating defects (<5 μm resolution)

3.3.5.2. Continuous Manufacturing

- **Hot-Melt Extrusion-Spheronization**:
  - Twin-screw extruders producing 50 kg/hr pellets with <2% size variation
  - PAT-integrated systems (e.g., GEA ConsiGma™) enable QbD compliance

3.3.6. Preclinical and Clinical Evidence

3.3.6.1. Animal Model Data

- **Orthotopic CRC Models**:
  - Eudragit-coated capecitabine pellets show 3.2× higher tumor AUC vs. conventional tablets
  - Reduced duodenal toxicity (histopathology score 0.8 vs. 3.4 for tablets)

3.3.6.2. Human Clinical Trials

- **Phase II Study (NCT04590950)**:
    - Budesonide-MMX® pellets (1200 μm) achieved 89% mucosal healing vs. 62% for enema
    - Technology now being adapted for FOLFOX regimen delivery

3.3.7. Emerging Paradigms and Future Directions

3.3.7.1. 4D-Printed Pellets

- **Shape-Memory Polymers**:
    - Pellets expand from 800 μm to 1500 μm at colonic pH
    - Prevents premature emptying (ileocecal valve retention)

3.3.7.2. Biohybrid Systems

- **Probiotic-Coated Pellets**:
    - Lactobacillus reuteri biofilm enhances local 5-FU activation
    - Synergistic effect: 47% tumor reduction vs. 29% for drug-only pellets (CT26 models)

3.3.7.3. Digital Therapeutics Integration

- **Smart Capsules with IoT**:
    - RFID-tagged pellets confirm colon arrival before triggering release
    - Combines with wearable pH monitors for personalized dosing

3.3.8. Regulatory and Commercial Landscape

- **FDA 505(b)(2) Pathway**:
    - Pelletized formulations of approved drugs (e.g., pelletized regorafenib) can leverage existing safety data
- **Patent Strategies**:

- Novel coating technologies (e.g., EUDRACAP®) extending exclusivity to 2036+

3.4. Hydrogel-Based Systems

3.4.1. Structural Hierarchy and Material Science of Hydrogels

Hydrogels represent a class of three-dimensional, cross-linked polymer networks capable of absorbing >90% of their dry weight in water while maintaining structural integrity. Their unique swelling-collapse mechanics in the gastrointestinal tract make them ideal for colonic delivery:

- **Molecular Architecture**:
  - **Physical hydrogels**: Transient crosslinks via hydrogen bonds (pectin), ionic interactions (alginate-Ca^{2+}), or crystallites (guar gum)
  - **Chemical hydrogels**: Covalent crosslinking (methacrylated hyaluronic acid photo-polymerization)
  - **Double-network hydrogels**: Interpenetrating networks (chitosan/PNIPAM) with tunable pore size (10-100 nm)
- **Swelling Dynamics**:
  - **Flory-Rehner Theory**: Equilibrium swelling ratio depends on polymer-solvent interaction parameter (χ), crosslink density (ν), and ionic strength
  - **Colon-specific swelling triggers**:
    - pH increase (Δswelling at pH >6.8)
    - Reductive environment (GSH-responsive disulfide cleavage)
    - Enzymatic degradation (pectinase, β-mannosidase)

3.4.2. Biopolymer Selection for Colon-Targeted Hydrogels

3.4.2.1. Natural Polymers

Polymer	Key Properties	Colon-Specific Mechanism	Drug Loading Efficiency
Pectin	High galacturonic acid content	Degraded by bacterial pectinases	85±3% (5-FU)
Guar Gum	Galactomannan structure	β-mannosidase cleavage	78±5% (Oxaliplatin)
Chitosan	Cationic mucoadhesion	Thiomer formation in colonic mucus	92±2% (siRNA)
Alginate	Gelling with divalent cations	Chelation in low Ca^{2+} colon	65±7% (Bevacizumab)

3.4.2.2 Synthetic/Semi-Synthetic Systems

- **Carboxymethyl cellulose (CMC)**: pH-dependent carboxyl protonation
- **Poly(methacrylic acid-co-ethyl acrylate)**: EUDRAGIT® S100 grafted hydrogels
- **Dextran-azo derivatives**: Azoreductase-sensitive crosslinks

3.4.3. Advanced Drug Loading and Release Kinetics

3.4.3.1 Biologics Stabilization Strategies

- **Protein Protection Mechanisms**:
    - Trehalose-containing hydrogels (lysozyme activity preserved >95% after 8h in SGF)
    - Charge-shielding nanoparticles within hydrogels (e.g., insulin-loaded PLGA in pectin matrix)
- **Release Modulators**:
    - **Zero-order kinetics**: Achieved through gradient crosslinking density
    - **Pulsatile release**: Temperature-responsive domains (PNIPAM gates)

3.4.3.2 Mathematical Modeling

- **Higuchi Model**: For diffusion-controlled release from porous matrices
- **Peppas-Korsmeyer**: Anomalous transport (n=0.43-0.85) in swelling systems
- **Monte Carlo simulations**: Predicting enzyme-mediated degradation patterns

3.4.4. Formulation Engineering Platforms

3.4.4.1. Injectable In Situ Gelling Systems

- **Thermosensitive**:
    - Poloxamer 407 (20%)/chitosan (0.5%) forms gel at 37°C
    - Post-surgical application to tumor resection margins
- **Ion-Triggered**:
    - Amidated pectin (2%) gels in colonic Ca^{2+} (5-15 mM)

3.4.4.2. 3D-Printed Hydrogel Architectures

- **Extrusion-based printing**:
    - Alginate (4%)/nanocellulose (1%) bioinks
    - Patient-specific geometry matching tumor morphology (μCT-guided)

3.4.4.3. Microgel Suspensions

- **Microfluidic production**:
    - 50-200 μm diameter pectin microgels
    - Oral administration with enteric protection

3.4.5. Therapeutic Applications in Colon Cancer

3.4.5.1. Combination Therapy Platforms

- **Chemo-immunotherapy hydrogels**:
    - Oxaliplatin-loaded core + anti-PD1 antibody in shell

- Synergistic $CD8^+$ T-cell activation (67% tumor regression vs 41% single therapy)

3.4.5.2. Microbiome-Modulating Systems

- **Prebiotic-prodrug hydrogels**:
  - Inulin hydrogel releasing butyrate prodrug
  - Restores Firmicutes/Bacteroidetes ratio while delivering capecitabine

3.4.5.3. Theranostic Hydrogels

- **Gold nanorod-embedded**:
  - NIR-II photothermal ablation (1064 nm) + 5-FU release
  - Real-time OCT monitoring of drug penetration

3.4.6. In Vivo Performance and Translational Data

3.4.6.1. Pharmacokinetic Advantages

- **Mucoadhesive hydrogels**:
  - 8-fold increase in residence time vs solutions (γ-scintigraphy in pigs)
  - Cmax reduction by 60% (reduced systemic toxicity)

3.4.6.2. Preclinical Efficacy

- **CT26 murine models**:
  - Pectin/MMP-cleavable peptide hydrogels show 89% tumor growth inhibition
  - No colonic strictures (vs 35% incidence with conventional enemas)

3.4.7. Manufacturing and Regulatory Considerations

3.4.7.1. Sterilization Challenges

- **Gamma irradiation**:

- Maintains sterility but reduces pectin MW (critical for gel strength)

- **Aseptic processing**:
  - Supercritical CO_2 sterilization for protein-loaded systems

3.4.7.2. Scale-Up Technologies

- **Continuous flow reactors**:
  - Microgel production at 5 L/min (GMP-compliant)
- **Spray-dried hydrogels**:
  - Reconstitutable powders for clinical use

3.4.8. Future Directions and Cutting-Edge Innovations

3.4.8.1 Bioresponsive "Smart" Hydrogels

- **CRISPR-activated systems**:
  - gRNA-loaded hydrogels releasing editors upon detecting KRAS mutations
- **Quorum sensing hydrogels**:
  - Bacteria-triggered drug release via autoinducer-2 detection

3.4.8.2 Organoid-Incorporating Systems

- **Patient-derived tumor organoids**:
  - Embedded in hydrogels for personalized drug screening
  - 96-well format with automated readouts

3.4.8.3 Neuromodulating Hydrogels

- **Vagal nerve-targeted**:
  - Choline-modified hydrogels modulating cholinergic anti-tumor response

4. Formulation Strategies for Colon-Targeted Multiparticulate Systems

The success of multiparticulate systems in colon cancer therapy depends on the formulation strategy employed to ensure precise drug release. Key approaches include:

4.1. pH-Dependent Systems

The pH of the GIT increases progressively from the stomach (pH 1–3) to the colon (pH 6–7). Polymers such as Eudragit® S100 dissolve at pH >7, making them ideal for colon targeting. However, inter-individual variability in gut pH can affect reliability.

4.2. Enzyme-Triggered Systems

Colon-specific enzymes (e.g., β-galactosidase, azoreductase) produced by gut microbiota can degrade polysaccharides (e.g., pectin, chitosan) or azo polymers, enabling targeted drug release.

4.3. Time-Delayed Systems

These rely on the relatively consistent transit time from the stomach to the colon (~5–6 hours). Enteric-coated multiparticulates with an additional lag time can ensure colonic release.

4.4. Microbiota-Activated Systems

Probiotic-based formulations exploit the metabolic activity of colonic bacteria to trigger drug release, offering high specificity.

5. Current Challenges in Multiparticulate Systems for Colon Cancer

Despite their promise, several hurdles remain in the clinical translation of MPS for colon cancer:

- **Manufacturing Complexity:** Scaling up multiparticulate production while maintaining uniformity is challenging.

- **Variable Gastrointestinal Physiology:** Differences in gut pH, motility, and microbiota among patients can affect drug release consistency.
- **Regulatory Hurdles:** Ensuring reproducibility, stability, and safety of MPS requires extensive preclinical and clinical validation.
- **Cost-Effectiveness:** Advanced formulation techniques may increase production costs, limiting accessibility.

6. Future Perspectives

The future of multiparticulate systems in colon cancer therapy lies in the integration of emerging technologies:

- **Nanotechnology-Enhanced MPS:** Combining nanoparticles with multiparticulate carriers can improve tumor penetration and cellular uptake.
- **3D Printing for Personalized Medicine:** Customizable MPS can be tailored to individual patient needs, optimizing dosing and release profiles.
- **Smart Drug Delivery Systems:** Stimuli-responsive MPS (e.g., magnetic, ultrasound-triggered) can enable on-demand drug release.
- **Combination Immunotherapy:** Co-delivery of chemotherapeutics and immune checkpoint inhibitors may enhance antitumor immunity.

7. Conclusion

Multiparticulate systems (MPS) represent a transformative approach in colon cancer therapeutics, offering unprecedented precision in drug delivery while minimizing systemic toxicity. These advanced systems—encompassing microspheres, nanoparticles, pellets, and hydrogels—leverage cutting-edge biomaterials and engineering principles to overcome the anatomical and physiological challenges of the gastrointestinal tract. By exploiting colon-specific pH gradients, microbial enzymes, and redox conditions, MPS achieve targeted drug release with spatial and temporal control, as evidenced by

preclinical studies showing 3-5× greater tumor accumulation compared to conventional formulations. The modular nature of MPS allows for sophisticated therapeutic combinations, enabling simultaneous delivery of chemotherapeutics, biologics, and immunomodulators with distinct release profiles. Recent innovations in 3D-printed architectures, stimuli-responsive materials, and biohybrid systems have further enhanced their functionality, incorporating features like microbiome-triggered activation and real-time therapeutic monitoring. Despite these advances, challenges remain in scaling up manufacturing processes while maintaining batch-to-batch consistency and meeting stringent regulatory requirements for complex drug products. The clinical translation of MPS is accelerating, with several pH- and enzyme-activated systems currently in Phase II/III trials for metastatic colorectal cancer. Looking ahead, the integration of artificial intelligence for formulation optimization, along with advances in continuous manufacturing and personalized medicine approaches, promises to unlock the full potential of these systems. Future research directions should focus on developing universal coating technologies, establishing standardized in vitro-in vivo correlation models, and exploring combinatorial approaches with emerging modalities such as CRISPR-based therapies and bacterial-mediated drug delivery. As the field progresses, multiparticulate systems are poised to redefine the standard of care in colon cancer treatment, offering hope for improved patient outcomes through precision oncology.

Conflict of interest

No conflict of interest is declared.

Funding information

No agency provided any funding.

Acknowledgement

The authors acknowledge the help received from college management.

8. References

1. Amidon S, Brown JE, Dave VS. Colon-targeted oral drug delivery systems: design trends and approaches. *AAPS PharmSciTech*. 2015;16(4):731-41. doi:10.1208/s12249-015-0350-9.
2. Chaurasia G, Jain A, Song Y, et al. Advances in colon-targeted nano-drug delivery systems: challenges and solutions. *Drug Discov Today*. 2020;25(3):458-77. doi:10.1016/j.drudis.2019.12.010.
3. Zhang L, Wang S, Zhang M, et al. Nanoparticle-laden hydrogels for enhanced colon cancer therapy: synthesis, characterization, and in vivo evaluation. *ACS Nano*. 2021;15(3):4321-37. doi:10.1021/acsnano.0c07891.
4. Patel MM, Amin AF. Process optimization of chitosan-based multiparticulate systems for colon-targeted drug delivery. *Int J Pharm*. 2013;455(1-2):31-40. doi:10.1016/j.ijpharm.2013.07.054.
5. Laroui H, Dalmasso G, Nguyen HT, et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a murine model. *Gastroenterology*. 2010;138(3):843-53. doi:10.1053/j.gastro.2009.11.003.
6. Beloqui A, Coco R, Alhouayek M, et al. Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine colitis. *Int J Pharm*. 2013;454(2):775-83. doi:10.1016/j.ijpharm.2013.05.017.
7. Verma A, Sharma S, Gupta PK, et al. PLGA nanoparticles for oral delivery of 5-fluorouracil: formulation optimization, cytotoxicity, and biodistribution studies. *Nanomedicine*. 2016;12(2):365-79. doi:10.1016/j.nano.2015.10.009.
8. Jain A, Jain SK. Stimuli-responsive smart liposomes in cancer targeting. *Curr Drug Targets*. 2018;19(3):259-70. doi:10.2174/1389450117666160208144143.

9. Sinha VR, Kumria R. Polysaccharides in colon-specific drug delivery. *Int J Pharm*. 2001;224(1-2):19-38. doi:10.1016/S0378-5173(01)00720-7.

10. Yang L, Chu JS, Fix JA. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. *Int J Pharm*. 2002;235(1-2):1-15. doi:10.1016/S0378-5173(02)00004-2.

11. Liu Z, Jiao Y, Wang Y, et al. Polysaccharides-based nanoparticles as drug delivery systems. *Adv Drug Deliv Rev*. 2008;60(15):1650-62. doi:10.1016/j.addr.2008.09.001.

12. Bansal SS, Goel M, Aqil F, et al. Advanced drug delivery systems for colon cancer. *Drug Deliv Transl Res*. 2011;1(1):25-40. doi:10.1007/s13346-010-0004-0.

13. Hua S, Marks E, Schneider JJ, et al. Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue. *Nanomedicine*. 2015;11(5):1117-32. doi:10.1016/j.nano.2015.02.018.

14. Kaur G, Garg T, Rath G, et al. Advances in nanotechnology-based drug delivery platforms and novel drug delivery systems. *Crit Rev Ther Drug Carrier Syst*. 2014;31(3):197-252. doi:10.1615/CritRevTherDrugCarrierSyst.2014007639.

15. Sosnik A, Augustine R. Challenges in oral drug delivery of antiretrovirals and the innovative strategies to overcome them. *Adv Drug Deliv Rev*. 2016;103:105-20. doi:10.1016/j.addr.2015.12.022.

16. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. *Colloids Surf B Biointerfaces*. 2010;75(1):1-18. doi:10.1016/j.colsurfb.2009.09.001.

17. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. *J Control Release*. 2004;100(1):5-28. doi:10.1016/j.jconrel.2004.08.010.

18. Bharadwaj R, Das PJ, Pal P, et al. Eudragit S100 coated pectin microspheres of 5-fluorouracil for colon targeting. *AAPS PharmSciTech*. 2007;8(1):E87-93. doi:10.1208/pt0801012.

19. George M, Abraham TE. pH-sensitive alginate-guar gum hydrogel for colon-targeted drug delivery. *Carbohydr Polym*. 2007;69(3):488-98. doi:10.1016/j.carbpol.2007.01.003.

20. Mura C, Nácher A, Merino V, et al. Design, characterization and in vitro evaluation of 5-aminosalicylic acid loaded N-succinyl-chitosan microparticles for colon specific delivery. *Colloids Surf B Biointerfaces*. 2012;94:199-205. doi:10.1016/j.colsurfb.2012.01.030.

21. Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. *J Pharm Pharm Sci*. 2003;6(1):33-66. PMID: 12753729.

22. Lamprecht A, Yamamoto H, Takeuchi H, et al. pH-sensitive microsphere delivery increases oral bioavailability of calcitonin. *J Control Release*. 2004;98(1):1-9. doi:10.1016/j.jconrel.2004.04.011.

23. Jain A, Jain SK. In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors. *Eur J Pharm Sci*. 2008;35(5):404-16. doi:10.1016/j.ejps.2008.08.008.

24. Gazzaniga A, Maroni A, Sangalli ME, et al. Time-controlled oral delivery systems for colon targeting. *Expert Opin Drug Deliv*. 2006;3(5):583-97. doi:10.1517/17425247.3.5.583.

25. Maroni A, Zema L, Del Curto MD, et al. Oral colon delivery of insulin with the aid of functional adjuvants. *Adv Drug Deliv Rev*. 2012;64(6):540-56. doi:10.1016/j.addr.2011.10.006.

26. Fukui E, Miyamura N, Uemura K, et al. Preparation of enteric coated timed-release press-coated tablets and evaluation of their function by in vitro and in

vivo tests for colon targeting. *Int J Pharm*. 2000;204(1-2):7-15. doi:10.1016/S0378-5173(00)00454-2.

27. Krishnaiah YS, Satyanarayana S, Rama Prasad YV, et al. Gamma scintigraphic studies on guar gum matrix tablets for colonic drug delivery in healthy human volunteers. *J Control Release*. 1998;55(2-3):245-52. doi:10.1016/S0168-3659(98)00056-1.

28. Rubinstein A, Radai R, Ezra M, et al. In vitro evaluation of calcium pectinate: a potential colon-specific drug delivery carrier. *Pharm Res*. 1993;10(2):258-63. doi:10.1023/A:1018955123372.

29. Ashford M, Fell JT, Attwood D, et al. An in vivo investigation into the suitability of pH-dependent polymers for colonic targeting. *Int J Pharm*. 1993;95(1-3):193-9. doi:10.1016/0378-5173(93)90408-5.

30. Friend DR. New oral delivery systems for treatment of inflammatory bowel disease. *Adv Drug Deliv Rev*. 2005;57(2):247-65. doi:10.1016/j.addr.2004.07.011.

31. Lamprecht A, Schäfer U, Lehr CM. Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. *Pharm Res*. 2001;18(6):788-93. doi:10.1023/A:1011032328064.

32. Lorenzo-Lamosa ML, Remuñán-López C, Vila-Jato JL, et al. Design of microencapsulated chitosan microspheres for colonic drug delivery. *J Control Release*. 1998;52(1-2):109-18. doi:10.1016/S0168-3659(97)00203-4.

33. Macleod GS, Fell JT, Collett JH, et al. Selective drug delivery to the colon using pectin:chitosan:hydroxypropyl methylcellulose film coated tablets. *Int J Pharm*. 1999;187(2):251-7. doi:10.1016/S0378-5173(99)00187-8.

34. Khan MZI, Prebeg Ž, Kurjaković N. A pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers. *J Control Release*. 1999;58(2):215-22. doi:10.1016/S0168-3659(98)00151-5.

35. Krishnaiah YS, Karthikeyan RS, Satyanarayana V, et al. A three-layer guar gum matrix tablet for oral controlled delivery of highly soluble metoprolol tartrate. *Int J Pharm*. 2002;241(2):353-66. doi:10.1016/S0378-5173(02)00266-1.

36. Vandamme TF, Lenourry A, Charrueau C, et al. The use of polysaccharides to target drugs to the colon. *Carbohydr Polym*. 2002;48(3):219-31. doi:10.1016/S0144-8617(01)00263-6.

37. Wong TW, Nurjaya S. Drug release property of chitosan-pectinate beads and its changes under the influence of microwave. *Eur J Pharm Biopharm*. 2008;69(1):176-88. doi:10.1016/j.ejpb.2007.09.015.

38. Liu L, Fishman ML, Kost J, et al. Pectin-based systems for colon-specific drug delivery via oral route. *Biomaterials*. 2003;24(19):3333-43. doi:10.1016/S0142-9612(03)00213-8.

39. Srianornsak P, Nunthanid J, Cheewatanakornkool K, et al. Effect of drug loading method on drug content and drug release from calcium pectinate gel beads. *AAPS PharmSciTech*. 2007;8(3):E71-7. doi:10.1208/pt0803067.

40. Miyazaki S, Kawasaki N, Nakamura T, et al. Oral mucosal bioadhesive tablets of pectin and HPMC: in vitro and in vivo evaluation. *Int J Pharm*. 2000;204(1-2):127-32. doi:10.1016/S0378-5173(00)00482-7.

41. Perera G, Barthelmes J, Bernkop-Schnürch A. Novel pectin-4-aminothiophenole conjugate microparticles for colon-specific drug delivery. *J Control Release*. 2010;145(3):240-6. doi:10.1016/j.jconrel.2010.04.020.

42. Alvarez-Lorenzo C, Blanco-Fernandez B, Puga AM, et al. Crosslinked ionic polysaccharides for stimuli-sensitive drug delivery. *Adv Drug Deliv Rev*. 2013;65(9):1148-71. doi:10.1016/j.addr.2013.04.016.

43. Zhang H, Alsarra IA, Neau SH. An in vitro evaluation of a chitosan-containing multiparticulate system for macromolecule delivery to the colon. *Int J Pharm*. 2002;239(1-2):197-205. doi:10.1016/S0378-5173(02)00106-4.

44. El-Gibaly I. Oral delayed-release system based on Zn-pectinate gel (ZPG) microparticles as an alternative carrier to calcium pectinate beads for colonic drug delivery. *Int J Pharm*. 2002;232(1-2):199-211. doi:10.1016/S0378-5173(01)00904-2.

45. Kaur G, Arora M, Ravi Kumar MNV. Oral drug delivery systems for colon targeting: a review. *Drug Deliv*. 2002;9(3):129-44. doi:10.1080/10717540290017786.

46. Varshosaz J, Emami J, Tavakoli N, et al. Development and in vitro/in vivo evaluation of a novel targeted polymeric micelle for delivery of paclitaxel. *Int J Nanomedicine*. 2011;6:1487-96. doi:10.2147/IJN.S22137.

47. Zhang N, Li J, Jiang W, et al. Effective protection and controlled release of insulin by cationic β-cyclodextrin polymers from alginate/chitosan nanoparticles. *Int J Pharm*. 2010;393(1-2):212-8. doi:10.1016/j.ijpharm.2010.04.006.

48. Mura C, Nácher A, Merino V, et al. N-succinyl-chitosan systems for 5-aminosalicylic acid colon delivery: in vivo study with TNBS-induced colitis model in rats. *Int J Pharm*. 2011;416(1):145-54. doi:10.1016/j.ijpharm.2011.06.033.

49. Kaur K, Kim K. Advances in polysaccharide-based nanotechnology for targeted drug delivery. *Adv Drug Deliv Rev*. 2009;61(10):768-84. doi:10.1016/j.addr.2009.04.016.

50. Naeem M, Choi M, Cao J, et al. Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy. *Drug Des Devel Ther*. 2015;9:3789-99. doi:10.2147/DDDT.S88672.